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Methods. Between March of 2011 and December of 2012 were performed 41 prostate brachytherapy applications with permanent
implants of 125-I seeds in patients diagnosed with prostate adenocarcinoma low and intermediate risk, as monotherapy or
combinedwith EBRT. The patient’s characteristicswere: 87.8%had stage≤T2a, 9.8% stage T2b and 2.4%T2c.Mean PSA: 6.73ng/ml
(range 4.06–16.7). 87.8% were Gleason≤6 and 7 (3 + 4) 12.2%. Median prostate volume was 33 cm3, only one patient had volume
53.8 cm3. System Quick-Link was used with real-time planiﬁcation, inserting a median of 16 needles and 60 seeds (range 38–82)
to cover PTV with 145Gy isodose in cases of brachytherapy with radical intent (92.6%) and 108Gy in the implants combined with
EBRT (7.4%).
Results. We obtained a mean V100 PTV of 96.96% (between 92.1–99.8%), perceiving a learning curve of which 97.5% of cases (39/41)
V100 was ≥95% as ESTRO recommendations. The total median D90 was 169.9Gy in implants performed with radical intent
(89.47%, >160Gy, 34/38) and 123.5Gy in combination with EBRT (100% >119Gy), following ESTRO recommendations. At 3 months,
we observed low levels in PSA in most of the cases.
Conclusion. The use of real-time planiﬁcation and Quick-Link construction seed system in brachytherapy for prostate carcinoma,
improves the learning curve of this technique. We achieved mean V100 and D90 with better compliance with the recommenda-
tions of ESTRO in most of the 41 patients treated with brachytherapy with this method of dosimetric calculation.
http://dx.doi.org/10.1016/j.rpor.2013.03.014
Clinical dosimetric on 100 patients with HDR breast brachytherapy with plastic multi-catheters
M. de Las Pen˜as Cabrera1, L. Díaz Gómez2, L. de Ingunza Barón2, E. Munive Álvarez2, E. González Calvo2,
I. Villanego Beltrán2, V. Díaz Díaz2, L. Gutierrez Bayard2, C. Salas Buzón2
1 Hospital Rey Juan Carlos, Móstoles, Madrid, Servicio de Oncología Radioterápica, Spain
2 Hospital Universitario Puerta Del Mar, “Unidad de Atención Integral Al Cáncer”, Spain
Objectives. To evaluate quality indexes in 3D-CT-based HDR breast brachytherapy and to compare between patients with partial
irradiation and those with boost.
Material and methods. This is a prospective study on 100 patients from March 2008 to December 2012. In 15 (15%) patients received
accelerated partial breast irradiation (APBI) and the remaining 85% had boost after external radiation therapy. Age was signiﬁ-
cantly lower in the boost group (49.79±9.03 vs. 69.60±6.68; p=0.0000000000002). Tumor size was signiﬁcantly bigger in the boost
group (18.8±10.31 vs. 12.8±7.75mm; p=0.03) while the margin was similar in both groups. Data are shown as mean±SD. The
Student’s t test was used for comparisons.
Results. Patients were planned using 2 planes in 2 cases of APBI (13.3%, 2/15) and in 35 cases of boost (41.2%) (p=0.04). In the rest 3,
planes were used. PTV, PTV90, DHI and VI-200 were signiﬁcantly higher in patients receiving APBI than in those with boost. PTV:
83.13±44.68 vs. 53.11±27.10; p=0.02); PTV90: 86.73±12.80 vs. 72.36±28.5; p=0.003; for DHI: 78.33±3.84 vs. 75.54±4.92; p=0.04
and 8.67±3.73 vs. 6.56±2.30; p=0.004 for VI-200. The rest of the studied indexes were similar in both groups: VI-150; V-200;
COIN; Dmax skin. DHI in APBI was signiﬁcant higher when using 3 planes vs. 2 planes 79.15±3.21 vs. 73.00±4.24; p=0.02. There
were no signiﬁcant correlations between tumor size and any of the studied quality indexes.
Conclusions. Quality indexes in 3D-CT based HDR were within the recommended ranges for patient planning, although COIN was
in the lower limit which should be improved. Quality indexes were better in the APBI group, especially when using 3 planes. These
differences are not related to a larger tumor size but probably to a wider planning margin in patients with partial irradiation. No
local recurrence.
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Introduction/Objective. To evaluate if glycosaminoglycan’s (GAG) administration as hyaluronic acid (HA) intravesical instillations
reduces the rate of acute and later radioinduced bladder toxicity. A review of the literature was done.
Materials and methods. Retrospective study of 131 patients diagnosed with cervical and endometrial cancer treated between May
2010 and December 2012 with high-dose rate brachytherapy (HDR-BT) with or without external beam radiotherapy (EBRT). 93/131
received an EBRT total dose of 45–50.4Gy delivered followed by brachytherapy (HDR-BT) 11Gy in 2 fractions. The remaining 38
patients received HDR-BT alone, 21Gy in 3 fractions. All of them received intravesical instillations of hyaluronic acid (HA) after
each HDR-BT fraction. 9/93 (10%) presented G1-2 toxicity before brachytherapy. RTOG/EORTC scale was used to evaluate acute
and late toxicity rates at 3, 6, and 12 months after HDR-BT. A review of the literature was made using Medline research with the
following criteria: HA prevention and gynecological cancer and radioinduced cystitis.
Results. No upgrading toxicity was observed in patients treated with combined HDR-BT and EBRT (93/131) during the follow-
up period. None of the patients (38/131) treated with exclusive HDR-BT had bladder toxicity. No adverse events related to HA
were observed. HA instillations have demonstrated effectiveness in relieving symptoms associated with interstitial cystitis,
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considering a similar biological pattern to radioinduced cystitis. 2 studies with these characteristics were found, showing that
HA instillations are effective in radioinduced cystitis prevention.
Conclusions. Intravesical instillations of hyaluronic acid are effective in preventing radiation cystitis. It is safe and well toler-
ated. Given the scarcity reports on this subject, it is difﬁcult to draw any ﬁrm conclusion about standard recommendations. A
prospective randomized control study with a large number of patients is recommended.
http://dx.doi.org/10.1016/j.rpor.2013.03.016
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Introduction. In 1999, American Brachytherapy Society (ABS) proposed prostate contour as clinical target volume (CTV) on prostate
brachytherapy. Many authors still use this CTV. In 2007 ESTRO recommended two new CTV according to risk of extraprostatic
extension (EPE): • CTV(ESTRO1) =prostate + 3mm around. • CTV(ESTRO2) =prostate + 3mm around excluding the rectal wall.
Purpose. 1. To demonstrate that CTV(ESTRO2) is the most appropriated to current knowledge on local development of prostate
cancer. 2. It is possible to obtain fair seed distributions respecting doses to target and organs at risk.
Methods and materials. Ninety-eight patients with low-risk prostate cancer treated with 125I seeds (dose 145Gy; CTV=prostate)
were included. Average age was 68.79 years, mean PSA was 6.30ng/ml. New CTV(ESTRO2) was deﬁned for every patients and
new planning was performed.
Results. Mean risk of EPE is 28.46% of which 15.93% are in the posterior direction. A CTV(ESTRO2) was planned for every case.
The mean CTV doses: V 100: 95.74%, V150: 47.65%, D90: 160.22Gy and organs at risk: Urethra D30: 190.70Gy and D10: 203.21Gy.
Rectum D2cc: 96.74Gy and D0.1cc: 183.50Gy All of them got a theoretical distribution of seeds that provided a curative dose to
this new CTV and respected the limiting dose for organs at risk. As expected, this extended CTV yield more dose to rectum but
not exceeding limitations. Urethral doses were similar in both plans.
Conclusion. CTV(ABS) seems to be insufﬁcient when risk of EPE is considered. CTV(ESTRO1) is excessive because the rectum,
which in most instances is inside the 3mm extension, is rarely involved by tumor. CTV(ESTRO2) seems to be suitable and it is
possible to plan the CTV proposed and obtain fair dosimetric results for CTV and organs at risk.
http://dx.doi.org/10.1016/j.rpor.2013.03.017
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Introduction. The prognosis of conservative treatment in choroidal melanoma, is marked by a number of factors with varying
degrees of signiﬁcance. It has found as an independent prognostic factor in the rapid regression of tumor after brachytherapy.
Dose rate is an important factor for the radiobiological viewpoint. The speed is early regression is indicative of metastasis.
Purpose. To correlate dose rate at the apex of tumor with speed of regression of the tumor height. To classify the treatments
performed according to the dose rate used. To study the relationship between the dose rate and disease-free survival of patients
treated with episcleral brachytherapy.
Method. Observational, retrospective and prospective study. Patients with uveal melanoma treated in our hospital by episcleral
brachytherapy with I-125. Descriptive variables of prognostic value regarding tumor data, data with respect to the applicator,
visual acuity both before treatment and in successive and scheduled revisions and survival data of patients and whether or not
disease free.
Results. Positive correlation was found between the dose rate and the rate of regression of the maximum height of the tumor.
However, the dose rate at the apex has no correlation with the change of size of the base nor changes in visual acuity. The dose
rate in the organs at risk is not related to changes in visual acuity.
Conclusions. Dose rate at apex tumor inﬂuences rate of regression of tumor height. So, you might have to be a prognostic factor.
http://dx.doi.org/10.1016/j.rpor.2013.03.019
